Focus: Hua Medicine is a Shanghai-based public biotech company specializing in small-molecule therapeutics across metabolic diseases, respiratory, neurology, infectious diseases, and oncology. The company operates at early-to-mid stage development with a diversified pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Hua Medicine to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 4 program in a high-market-value indication with potential regulatory approval and market entry potential.
Help build intelligence for Hua Medicine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hua Medicine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Phase 4 program in established therapeutic area with clear regulatory pathway and commercialization readiness.
Phase 3 biologic asset in specialized endocrinology space with defined patient population and reimbursement pathways.
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
Shanghai firm's innovative diabetes drug gains approval in HK - citynewsservice.cn
Shanghai firm's innovative diabetes drug gains approval in HK citynewsservice.cn
FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable
The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs.
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China - The Tribune
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China The Tribune
Hua Medicine secures Hong Kong approval for first-in-class diabetes pill - The Pharma Letter
Hua Medicine secures Hong Kong approval for first-in-class diabetes pill The Pharma Letter
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China - TheWire.in
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China TheWire.in
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.
Effects of Dorzagliatin, a Glucokinase Activator, on α- and β-Cell Function in Individuals With Impaired and Normal Glucose Tolerance.
Showing 5 of 10 publications